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0959-8049/ª 2018 Elsevier Ltd. All righAbstract Introduction: Health-related quality of life (HRQOL) is increasingly recognised as
an important end-point in cancer clinical trials. The concept of minimally important difference
(MID) enables interpreting differences and changes in HRQOL scores in terms of clinical
meaningfulness. We aimed to estimate MIDs for interpreting group-level change of European
Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30
(EORTC QLQ-C30) scores in patients with malignant melanoma.
Methods: Data were pooled from three published melanoma phase III trials. Anchors relying
on clinician’s ratings, e.g. performance status, were selected using correlation strength ande Department, European Organization for Research and Treatment of Cancer, 83/11 Avenue E. Mounier,
rtc.org (J.Z. Musoro).
ts reserved.
J.Z. Musoro et al. / European Journal of Cancer 104 (2018) 169e181170clinical plausibility of associating the anchor/EORTC QLQ-C30 scale pair. HRQOL change
was evaluated between time periods that were common to all trials: start of treatment to
end of treatment and end of treatment to end of follow-up. Three change status groups were
formed: deteriorated by one anchor category, improved by one anchor category and no
change. Patients with greater anchor change were excluded. The mean change method and
linear regression were used to estimate MIDs for change in HRQOL scores within the group
and between the groups of patients, respectively.
Results: MIDs varied according to QLQ-C30 scale, direction (improvement versus deteriora-
tion), anchor and period. MIDs for within-group change ranged from 4 to 18 points (improve-
ment) and 16 to 4 points (deterioration), and MIDs for between-group change ranged
from 3 to 16 points and from 16 to 3 points. MIDs for most of QLQ-C30 scales ranged
from 5 to 10 points in absolute values.
Conclusions: These results are useful for interpreting changes in EORTC QLQ-C30 scores
over time and for performing more accurate sample size calculations in adjuvant melanoma
settings.
ª 2018 Elsevier Ltd. All rights reserved.1. Introduction
Health-related quality of life (HRQOL) is increasingly
recognised as an important end-point in cancer clinical
trials [1].Understanding the amount of change inHRQOL
scores that are clinically relevant is crucial for interpreta-
tion. The concept of minimally important difference
(MID) enables the interpretation of differences between
groups and changes over time in HRQOL scores in terms
of clinical meaningfulness [2e6]. MID is defined as ‘the
smallest difference in score in the outcome of interest that
informed patients or informed proxies perceive as impor-
tant, either beneficial or harmful, andwhichwould lead the
patient or clinician to consider a change in the manage-
ment’ [2]. MIDs are commonly determined by anchor-
based and distribution-based methods [7]. Anchor-based
methods express differences or change in HRQOL scores
by linking specific HRQOL domains to clinical variables
that have known clinical relevance [3,8e10] or to patient-/
physician-derived ratings of change in the specific domain
[4e6]. The usefulness of anchor-based MIDs is reliant on
the anchor selected, how discriminant groups are defined
with respect to that anchor and the strength of the rela-
tionship (conceptually and empirically) between the an-
chor and the target HRQOL domain [11]. Distribution-
based methods rely on the statistical distribution of
HRQOL scores, e.g. standard deviation (SD) criteria or
the standard error ofmeasurement (SEM) [12,13]. Because
distribution-based methods do not consider patients’/cli-
nicians’ perspective, they have been recommended to be
used as supportive evidence to anchor-based methods [7].
The European Organisation for Research and Treat-
ment for Cancer Quality of life Questionnaire core 30
(EORTC QLQ-C30) is widely used to assess HRQOL in
cancer patients [14]. Osoba et al. [4] published guidelines
for interpreting small (5e10 points), moderate (10e20
points) and large changes (>20 points) in EORTC QLQ-C30 scores using a global patient rating of change as an-
chor, in patients with breast and small-cell lung cancer. In
an early application of clinical anchors, King [3] compiled
published evidence about differences in EORTC QLQ-
C30 scores between groups for multiple cancer sites and
clinical anchors and found that the score range for small,
moderate and large effects differed between HRQOL
scales. More recent guidelines by Cocks et al. [5,6] high-
lighted the need to differentiate not only between the
EORTC QLQ-C30 scales but also between the direction
of change (improvement versus deterioration) and clinical
settings. This implies that a global rule for MIDs appli-
cable to all situations is highly unlikely [7,11,15].
This study aims to provideMID estimates for EORTC
QLQ-C30 scales in patients with malignant melanoma
who undergo adjuvant treatment. We focused on exam-
ining MIDs for group-level change (both within and be-
tween groups) inHRQOL scores over time [16]. There are
currently no MID guidelines for the EORTC QLQ-C30
specific to malignant melanoma. In contrast to Osoba
et al. [4], we used multiple clinical anchors that were
available in our database. Furthermore, the guidelines of
King [3] and Cocks et al. [5,6] were based on meta-
analyses of published studies, pooling across cancer
sites, whereas we used individual patient data from
archived EORTC melanoma trials.
2. Methods
2.1. Data description
Data were pooled from three published adjuvant mela-
noma phase III EORTC trials. Trial 1 assessed the effect
of two regimens of interferon of intermediate dose
versus observation alone in patients with stage IIb/III
melanoma after surgery and enrolled 1388 patients [17].
Trial 2 compared adjuvant immunotherapy with anti-
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placebo after complete resection of high-risk stage III
melanoma and enrolled 951 patients [18,19]. Trial 3
compared the effect of adjuvant therapy with PEG-
Intron to observe after adequate dissection of the
regional lymph in American Joint Committee on Cancer
stage III melanoma and enrolled 1256 patients [20]. All
three trials assessed HRQOL using the EORTC QLQ-
C30 at baseline, during treatment and on several
follow-up time points after the end of treatment. When
pooling, three key time points were identified that were
common across all three trials: (i) Start of treatment
(T1); time point before or on the first day of treatment
administration. If no treatment was administered, then
T1 was the time point before or on the date of ran-
domisation. (ii) End of treatment (T2); last day of
protocol treatment administration. Patients who were
under observation alone did not contribute data at T2.
(iii) End of follow-up (T3); the last day of the protocol
follow-up period. For patients under observation, T3
was the last day after baseline.
2.2. The EORTC QLQ-C30
The EORTC QLQ-C30 comprises 30 items, 24 of which
are aggregated into nine multi-item scales, i.e. five
functioning scales: physical functioning (PF), role
functioning (RF), cognitive functioning (CF), emotional
functioning (EF) and social functioning (SF); three
symptom scales: fatigue (FA), pain (PA) and nausea/
vomiting (NV) and one global health status (QL) scale.
The remaining six single items assess symptoms: dysp-
noea (DY), appetite loss (AP), sleep disturbance (SL),
constipation (CO), diarrhoea (DI) and financial impact
(FI).
Trial 1 used version 2 of the QLQ-C30, whereas trial
2 and 3 used version 3. The two versions differ only in
the response categories of questions 1e5 (in the PF
domain), coded as yes/no in version 2, whereas version 3
uses a four-point Likert scale ranging from ‘not at all’ to
‘very much’. The scoring of the EORTC QLQ-C30
scales was done according to the EORTC QLQ-C30
scoring manual [14], with the means of the raw scores
for each scale transformed to fall between 0 and 100.
For consistency in signs of the change scores across the
various scales, the symptom scores were reversed to
follow the functioning scales interpretation, i.e. all scales
were scored such that 0 represents the worst possible
score and 100, the best possible score. The FI scale was
omitted from the analysis because suitable anchors were
not available.
2.3. Clinical anchors
Anchors were constructed using clinical data from
physician examinations, common terminology criteria
for adverse events (CTCAE) and laboratory results thatwere available in the trial data sets. Anchors were
initially selected based on the strength of correlation
with the corresponding QLQ-C30 scale. We prioritised
anchors with correlations of j0.30j as proposed by
Revicki et al. [7], and where achievable, anchors with
stronger correlations were targeted [21]. The selected
anchors were further verified for clinical plausibility by a
panel of melanoma and HRQOL experts to avoid
spurious findings. This panel was also tasked to identify
clinically relevant changes for each of the selected an-
chors. For each QLQ-C30 scale, multiple anchors could
be selected. Details on the anchor selection procedures
have been described by Musoro et al. [16]. The retained
anchors comprised World Health Organisation perfor-
mance status (PS) and 7 CTCAEs (gastrointestinal
disorder, anorexia, pain, fatigue, immune disorder,
diarrhoea and nervous system disorder). The PS was
scored between 0 (no symptoms of cancer) and 4 (bed-
bound), whereas the CTCAEs were graded between
0 (no toxicity) and 4 (life-threatening).
2.4. Definition of clinical change groups
Three clinical change status groups (CCGs) were defined
after consultation with our panel of clinical experts:
deterioration (worsened by 1 anchor category), stable
(no change in anchor category) and improvement
(improved by 1 anchor category). Patients who changed
by 2 or more categories of an anchor were considered to
be above the ‘minimal’ expected change and so were
excluded from data sets used to estimate mean change
and MIDs.
2.5. Data analysis
Individual-level change scores of the EORTC QLQ-C30
scales and their corresponding anchors were computed
between T1 and T2 and between T2 and T3. Only sub-
jects with both EORTC QLQ-C30 and anchor data
available for a given pair of time points contributed to
calculation of change scores.
Two anchor-based methods were then used to esti-
mate MIDs for improvements and deterioration for
each EORTC QLQ-C30 scale and its corresponding
anchors. The primary method involved calculating the
mean HRQOL change score for the improvement and
deterioration CCGs. This is applicable for interpreting
change within a group of patients, and it is analogous to
the mean HRQOL change score over time for a single
treatment group in a trial. Effect sizes (ESs) were
computed by dividing the mean change HRQOL score
between adjacent time points (e.g. T1 and T2) by the SD
of the HRQOL scores at the earlier time point (T1).
Only mean change scores with an ES of >0.2 or 0.8
were considered appropriate for inclusion as MIDs. This
was based on Cohen’s [13] recommendations that an ES
of 0.2 is small, 0.5 is moderate and 0.8 is large. The
J.Z. Musoro et al. / European Journal of Cancer 104 (2018) 169e181172rationale here was that observed effect sizes <0.2 re-
flected changes that were clinically unimportant, and
those 0.8 were clearly more than minimally important.
We also compared the difference in change scores be-
tween the improvement (or deterioration) CCG and no
change CCG using analysis of variance (ANOVA).
The secondary method involved linear regression
applied to compare change scores for subjects in the
improvement (or deterioration) CCGs versus the stable
CCG. For a given EORTC QLQ-C30 scale/anchor pair,
separate models were fitted for improving and deterio-
rating scores. The outcome variable was the HRQOL
change score, and the covariate was a binary anchor vari-
able, coded as ‘stable’Z 0 and ‘improvement’Z 1 when
modelling improvement and ‘stable’ Z 0 and
‘deterioration’ Z 1 when modelling deterioration. The
resulting slope parameters correspond to the mean change
score for improvement and deterioration, respectively.This
is useful for interpreting changes between groups of pa-
tients, and it is analogous to comparing the meanHRQOL
change score in a target treatment group to a control group
in a trial. For a given HRQOL scale, the anchor-based
estimates from multiple anchors were triangulated to a
single value via a correlation-based weighted average.
Distribution-based techniques were used as supportive
methods by estimating the 0.2 SD, 0.3 SD, 0.5 SD and
SEM separately at T1, T2 and T3. These techniques have
previously been used in the literature to estimate MIDs
[7]. However, because these estimates rely solely on the
statistical distribution of the HRQOL scores and do not
include an inherent valuation of clinical relevance, they
are used to give context to our derived anchor-based es-
timates. Testeretest reliability estimates to compute
SEM for the QLQ-C30 were obtained from Hjermstad
et al. [22]. All statistical analyses were performed using
the SAS software [23]. An in-depth description of the
statistical methodology, including the anchor selection
process, has previously been published [16].3. Results
The baseline demographic and clinical characteristics of
the study population are presented in Tables 1 and 2.
The characteristics of the patients across the 3 trials
were similar. In Table 3, the descriptive statistics of the
QLQ-C30 scale scores at T1, T2 and T3 are summarised.
The distribution of the various scale scores was similar
across the different time points. The time period (in
months) between T1 and T2 ranged from 0.1 to 24.2
with a mean of 10.4 (SD Z 6.1) for trial 1, from 0 to
38.4 with a mean of 12.3 (SD Z 12.8) for trial 2 and
from 0.1 to 57 with a mean of 23.7 (SDZ 16.6) for trial
3. The period between T2 and T3 ranged from 0 to 31.3
with a mean of 8.9 (SDZ 6.4) for trial 1, from 0 to 64.4
with a mean of 11.2 (SD Z 11) for trial 2 and from 0.5
to 64.4 with a mean of 27.5 (SD Z 19.7) for trial 3.Cross-sectional correlations of the QLQ-C30 scale
scores with their corresponding selected anchors (at T1,
T2 and T3) and correlations between their change scores
(between T2eT1 and T3eT2) are presented in Table 4.
At least one anchor was constructed for each QLQ-C30
scale, except for the constipation scale for which no
suitable anchors were found. The cross-sectional corre-
lations ranged from 0.16 to 0.76 in absolute value, with
more than 90% of the correlation coefficients being
above the 0.3 threshold [7]. Much lower correlations
(range: 0.1e0.53) were observed between the change
scores.
The distribution of patients across the different an-
chor categories is summarised in Table A.1. According
to the anchors, most patients remained stable (63%e
88%), for both periods between T2 & T1 and T3 & T2.
Relatively low proportions of patients either improved
(4%e20%) or deteriorated (2%e11%).
Table 5 presents the range of estimated MID values
from the mean change method and the linear regression
for each HRQOL scale, across multiple anchors and over
time (change between T2 & T1 versus T3 & T2). MID
estimates are only presented for scales with at least one
appropriate anchor or for which CCG has an ES of >0.2
or0.8. Detailed results on the estimates per anchor from
the mean change method and the linear regression are
presented in Tables A.2 and A.3, respectively. Generally,
the MID estimates varied by scale, direction of change
scores (improvement versus deterioration), selected an-
chor and time point. This is illustrated in Fig. 1, in which
estimates from the mean change method in Table 5 are
plotted along with their 95% confidence intervals (CIs).
Although the MID estimates for change between T1 and
T2 were comparable to those for change between T2 and
T3, relatively wider CIs were observed in the latter time
period, reflecting the relatively smaller sample size. The
MID estimates were always in the expected direction ac-
cording to the anchor, i.e. positive versus negative change
scores within the improvement versus deterioration CCG,
respectively. Based on ANOVA, the difference in change
scores between the improvement (or deterioration) CCG
and no change CCG for most of the EORTC QLQ-C30
scales were statistically significant (p-value <0.05). Non-
significant differences were mostly observed among the
CCGs with an ES of<0.2. As shown in Table 5, generally
the MIDs for interpreting within-group change in
HRQOL scores (estimated using the mean change
method) ranged from 4 to 18 points and16 to4 points
for improvement and deterioration, respectively. MIDs
for between-group change (estimated using the linear
regression) ranged from 3 to 16 points and 16 to 3
points for improvement and deterioration, respectively.
For the majority of the QLQ-C30 scales, the estimated
MIDs ranged from 5 to 10 points in absolute values.
The results in Table 5 were further summarised to
single MID values per scale in Table 6 by taking a
correlation-weighted average across multiple anchors.
Table 1
Selected baseline demographic and clinical characteristics of the patients by study.
Study 18952
(N Z 1388)
Study 18071
(N Z 951)
Study 18991
(N Z 1256)
Total
(N Z 3595)
Gender, N (%)
Male 771 (55.5) 589 (61.9) 731 (58.2) 2091 (58.2)
Female 616 (44.4) 362 (38.1) 525 (41.8) 1503 (41.8)
Missing 1 (0.1) 0 (0.0) 0 (0.0) 1 (0.0)
Country, N (%)
United Kingdom 142 (10.2) 36 (3.8) 327 (26.0) 505 (14.0)
Italy 91 (6.6) 144 (15.1) 229 (18.2) 464 (12.9)
The Netherlands 261 (18.8) 23 (2.4) 152 (12.1) 436 (12.1)
France 181 (13.0) 144 (15.1) 106 (8.4) 431 (12.0)
Germany 140 (10.1) 76 (8.0) 103 (8.2) 319 (8.9)
The United States 0 (0.0) 213 (22.4) 0 (0.0) 213 (5.9)
Poland 167 (12.0) 11 (1.2) 28 (2.2) 206 (5.7)
Belgium 116 (8.4) 16 (1.7) 68 (5.4) 200 (5.6)
Switzerland 46 (3.3) 41 (4.3) 44 (3.5) 131 (3.6)
Bulgaria 46 (3.3) 0 (0.0) 29 (2.3) 75 (2.1)
Russian 21 (1.5) 54 (5.7) 0 (0.0) 75 (2.1)
Australia 0 (0.0) 37 (3.9) 36 (2.9) 73 (2.0)
Spain 27 (1.9) 11 (1.2) 35 (2.8) 73 (2.0)
Portugal 38 (2.7) 0 (0.0) 33 (2.6) 71 (2.0)
Denmark 0 (0.0) 59 (6.2) 0 (0.0) 59 (1.6)
Croatia 14 (1.0) 0 (0.0) 31 (2.5) 45 (1.3)
Others* 98 (7.1) 86 (9.0) 35 (2.8) 219 (6.1)
Number of positive lymph nodes, N (%)
0e1 712 (51.3) 437 (46.0) 678 (54.0) 1827 (50.8)
2e4 389 (28.0) 321 (33.8) 423 (33.7) 1133 (31.5)
5 151 (10.9) 192 (20.2) 148 (11.8) 491 (13.7)
Unknown/missing 136 (9.8) 1 (0.1) 7 (0.6) 144 (4.0)
Performance status, N (%)
0 1199 (86.4) 890 (93.6) 1061 (84.5) 3150 (87.6)
1 180 (13.0) 61 (6.4) 195 (15.5) 436 (12.1)
Missing 9 (0.6) 0 (0.0) 0 (0.0) 9 (0.3)
Age
Mean (SD) 48.55 (13.46) 51.10 (12.86) 48.80 (12.35) e
Interquartile 39.0e59.0 42.0e61.0 40.0e58.0 e
Weight (kg)
Mean (SD) 75.47 (15.15) 82.43 (18.20) 77.08 (14.99) e
Interquartile 65.0e84.5 70.0e92.0 66.0e85.6 e
Others* Comprise countries with total percentage < 1% (Canada, Czech Republic, Austria, Turkey, Finland, Sweden, Estonia, Norway, Slovenia,
Israel, Serbia, Hungary and Slovakia).
SD, standard deviation.
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scale for use in practice. Furthermore, in Table 6, we
also compared the anchor-based MIDs to estimates from
commonly used distribution-based approaches in the
literature. The distribution-based estimates for each
QLQ-C30 scale were very similar across T1, T2 and T3.
For a particular distribution-based approach, theTable 2
Distribution of patients by baseline disease stage.
Study 18952 (N Z 1388) Study 18071 (N Z 951)
Tumour stage N (%) Tumour stage
TXN2M0 749 (54.0) Stage III B
T4N0M0 355 (25.6) Stage III C ( 4LNþ)
TXN1M0 283 (20.4) Stage III A
Missing 1 (0.1) Stage III C (1e3 LNþ)estimates across the different time points were mostly
within a <1 point range for a given QLQ-C30 scale.
Therefore, only results at T1 are reported in Table 6. The
anchor-based MID estimates tended to be larger than the
0.2 SD and smaller than the 0.5 SD. Most of the anchor-
based estimates were closer to both the 0.3 SD and the 1
SEM.Study 18991 (N Z 1256)
N (%) Tumour stage N (%)
420 (44.2) TanyN2MO 743 (59.2)
193 (20.3) TanyN1M0 508 (40.4)
186 (19.6) TxN0M0 5 (0.4)
152 (16.0)
Table 3
Summary statistics of the EORTC QLQ-C30 scale scores at T1, T2 and T3.
Scale (n Z 1575e1840)
PF RF SF EF CF QL PA FA NV AP DY DI SL CO
T1
Median 93.3 83.3 100.0 83.3 100.0 75.0 100.0 66.7 100.0 100.0 100.0 100.0 100.0 100.0
Mean
(SD)
86.1
(18.7)
76.5
(27.3)
83.7
(22.7)
79.5
(20.5)
88.3
(17.9)
70.2
(20.0)
84.1
(21.9)
69.6
(26.0)
92.4
(14.3)
82.1
(27.9)
88.6
(21.4)
89.5
(19.5)
81.5
(25.8)
93.3
(16.7)
T2
Median 100.0 100.0 100.0 83.3 100.0 75.0 100.0 77.8 100.0 100.0 100.0 100.0 100.0 100.0
Mean
(SD)
87.8
(17.7)
80.8
(24.8)
85.4
(21.8)
79.7
(21.0)
85.9
(20.2)
71.3
(20.3)
84.0
(22.8)
72.2
(24.0)
94.0
(13.6)
86.2
(24.1)
87.2
(21.8)
89.2
(20.5)
79.2
(26.6)
92.0
(18.8)
T3
Median 100.0 100.0 100.0 83.3 100.0 75.0 100.0 77.8 100.0 100.0 100.0 100.0 100.0 100.0
Mean
(SD)
86.7
(19.7)
81.1
(27.2)
85.6
(23.8)
80.2
(21.5)
86.5
(20.2)
72.0
(22.1)
84.1
(23.9)
75.5
(24.9)
94.9
(14.3)
90.1
(21.7)
87.9
(21.8)
92.9
(17.4)
79.4
(27.2)
92.3
(17.8)
T1, T2 and T3 are time points for start of treatment, end of treatment and end of follow-up, respectively. AP, appetite loss; CF, cognitive
functioning; CO, constipation; DI, diarrhoea; DY, dyspnoea; EF, emotional functioning; FA, fatigue; NV, nausea/vomiting; PA, pain; PF, physical
functioning, QL, global quality of life; RF, role functioning; SF, social functioning; SL, sleep disturbance; SD, standard deviation; EORTC QLQ-
C30, European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30.
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Our study determined MIDs for group-level change of
the EORTC QLQ-C30 scores over time, using individual
patient data pooled across three published international
randomised EORTC adjuvant melanoma clinical trials.
Anchors for each QLQ-C30 scale were selected based on
both the statistical correlation and clinical plausibility.
Multiple anchors were selected for most QLQ-C30
scales. The cross-sectional correlations between the an-
chors and their corresponding scales were usually
greater than the recommended 0.3 correlation threshold
[7]. However, lower correlations were observed when
considering the changes over time, which may be
attributed to cumulative measurement error.
The use of multiple anchors per scale provided some
reassurance about the plausibility of the estimated
MIDs. Despite the modest correlation between the an-
chors/scales change scores, the estimated MIDs were
often within a small range (generally < 5 points range)
and were also in the expected direction of change ac-
cording to the anchor.
Similar to recent findings on MIDs for the QLQ-C30
by Cocks et al. [5,6] and Maringwa et al. [8,9], we
observed that MIDs vary by scales as well as by the
direction of change (improvement versus deterioration).
Furthermore, akin to the study by Maringwa et al. [8,9],
there were no systematic differences in the magnitude of
change between deteriorating and improving scores.
This is in contrast to the study by Cocks et al. [6] and
other studies that assessed MIDs for the Functional
Assessment of Cancer Therapy questionnaires [24,25], in
which estimates for deterioration tended to be larger
than those for improvement. However, we noted that
the latter studies used a patient- or clinician-rated global
rating of change as anchors, whereas our study and
those of Maringwa et al. applied clinical anchors. It willbe interesting to further examine this observation in
other studies.
Our MID estimates across many scales were some-
what within the suggested 5e10 points range suggested
by Osoba et al. [4], as shown in Table 5. Cocks et al. [5,6]
and Maringwa et al. [8,9] also made similar observa-
tions, which is reassuring. However, as pointed out by
Cocks et al. [5,6], we also observed that the thresholds
for some scales could be much lower. For example, the
MIDs for the EF and CF scales could be as low as 3
points. On the other hand, much bigger thresholds were
observed for scales such as RF and AP, whereas MIDs
for the AP scale could be as high as 18 points. This re-
inforces the evidence that there is no single global
standard for clinically meaningful change, and scale-
specific MIDs should therefore be selected with more
caution.
For any given QLQ-C30 scale, no remarkable dif-
ferences were observed among MIDs for change scores
between T1 and T2 and between T2 and T3. This is
probably because the patients’ HRQOL in these adju-
vant melanoma studies were relatively stable over time
as shown by the mean scores at T1, T2 and T3 in Table
3. Furthermore, according to the anchors, the majority
of the patients remained stable over time or changed by
only one category (Table A.1). Comparable estimates
(results not shown) were also obtained from applying
the mean change method to the merged data of all
possible pairwise time point differences of HRQOL
scores (where a subject can contribute multiple change
scores that are calculated across different pairs of time
points). We also made a distinction between MIDs for
interpreting within-group changes, obtained from the
mean change method, and MIDs for interpreting
changes between groups, obtained from the linear
regression. Estimates from both approaches were often
in the same range.
Table 4
Cross-sectional correlations of the EORTC QLQ-C30 scale scores with anchors and correlations between their change scores.
Scale Anchor Cross-sectional Change scores
T1 T2 T3 T2eT1 T3eT2
PF Performance status 0.39 0.41 0.35 0.23 0.28
CTCAE anorexia 0.41 0.34 0.35 0.18 0.26
CTCAE fatigue 0.38 0.36 0.29 0.19 0.16
RF Performance status 0.36 0.51 0.48 0.22 0.35
CTCAE gastrointestinal 0.44 0.38 0.39 0.26 0.23
CTCAE anorexia 0.45 0.44 0.45 0.24 0.3
CTCAE fatigue 0.53 0.46 0.4 0.24 0.24
SF Performance status 0.35 0.50 0.47 0.22 0.32
CTCAE gastrointestinal 0.43 0.41 0.37 0.25 0.24
CTCAE anorexia 0.46 0.44 0.4 0.26 0.26
CTCAE fatigue 0.45 0.44 0.4 0.23 0.2
EF Performance status 0.18 0.37 0.3 0.12 0.24
CTCAE nervous system 0.44 0.48 0.4 0.21 0.17
CTCAE anorexia 0.34 0.41 0.3 0.14 0.21
CF Performance status 0.28 0.36 0.3 0.14 0.18
CTCAE nervous system 0.39 0.36 0.32 0.12 0.19
CTCAE fatigue 0.39 0.37 0.3 0.11 0.13
QL Performance status 0.38 0.48 0.44 0.26 0.36
CTCAE nausea 0.45 0.42 0.38 0.24 0.23
CTCAE gastrointestinal 0.48 0.39 0.38 0.3 0.3
CTCAE anorexia 0.49 0.46 0.46 0.26 0.32
PA Performance status 0.26 0.43 0.44 0.18 0.3
CTCAE pain 0.39 0.43 0.35 0.19 0.28
CTCAE immune 0.38 0.49 0.44 0.26 0.24
FA Performance status 0.39 0.49 0.46 0.26 0.36
CTCAE gastrointestinal 0.53 0.42 0.45 0.3 0.3
CTCAE anorexia 0.55 0.49 0.5 0.26 0.34
CTCAE fatigue 0.63 0.55 0.45 0.3 0.3
NV CTCAE nausea 0.67 0.73 0.58 0.43 0.31
CTCAE gastrointestinal 0.61 0.57 0.5 0.33 0.35
CTCAE anorexia 0.51 0.53 0.49 0.21 0.4
AP CTCAE nausea 0.6 0.53 0.54 0.3 0.24
CTCAE gastrointestinal 0.71 0.60 0.62 0.41 0.38
CTCAE anorexia 0.76 0.72 0.67 0.43 0.52
DY Performance status 0.37 0.35 0.34 0.15 0.2
CTCAE fatigue 0.38 0.42 0.33 0.15 0.21
DI CTCAE gastrointestinal 0.38 0.38 0.34 0.26 0.37
CTCAE diarrhoea 0.76 0.68 0.56 0.5 0.53
SL Performance status 0.16 0.28 0.3 0.09 0.18
T1, T2 and T3 are time points for the start of treatment, end of treatment and end of follow-up, respectively. AP, appetite loss; CF, cognitive
functioning; CO, constipation; DI, diarrhoea; DY, dyspnoea; EF, emotional functioning; FA, fatigue; NV, nausea/vomiting; PA, pain; PF, physical
functioning, QL, global quality of life; RF, role functioning; SF, social functioning; SL, sleep disturbance; CTCAE, common terminology criteria
for adverse events; EORTC QLQ-C30, European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30.
Example of cross-sectional correlations: PF at T1 versus performance status at T1Z 0.39, PF at T2 versus performance status at T2Z0.41 and
PF at T3 versus performance status at T3 Z 0.35.
Example of change score correlations: (PF at T2  PF at T1) versus (Performance status at T2 e Performance status at T1)Z 0.23 and (PF at T3
e PF at T2) versus (Performance status at T3 e Performance status at T2) Z 0.28.
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often like simple guidance, results such as those pre-
sented in this article are often complex, as a consequence
of there being numerous anchors, various distribution-
based criteria and various HRQOL scales. In Table 5,
we represented this complexity as the range of MIDs
generated by the various anchors. However, we
acknowledge end-users may find such a range of options
confusing, wondering which they should use. So to
provide a single MID value per QLQ-C30 scale, we
further simplified by calculating a correlation-weighted
average across multiple anchors. End-users can chooseto work with either the ranges provided in Table 5 or the
single values provided in Table 6, whichever they feel
most comfortable with.
A limitation of our study is that anchor-based MIDs
could only be estimated for QLQ-C30 scales for which a
suitable anchor was available in the database. For
example, no suitable anchors were found for the con-
stipation (CO) scale. Different anchors also represent
different categorisations of clinical relevance that may
or may not exceed a ‘true’ MID. Furthermore, the
available anchors relied exclusively on clinical observa-
tions or interpretations. The potentially inflated MID
Table 5
Range of anchor-based MID estimates from the mean change method and linear regression.
Scale Mean change method Linear regression
T2eT1 T3eT2 T2eT1 T3eT2
Improvement (deterioration) Improvement (deterioration) Improvement (deterioration) Improvement (deterioration)
PF 5 to 7 (6) 4 to 6 (9 to 6) 4 to 6 (6) 5 to 7 (8 to 5)
RF 11 to 15 (6) 7 to 16 (14 to 8) 9 to 12 (8) 7 to 14 (16 to 9)
SF 6 to 11 (8 to 5) 6 to 11 (12 to 6) 4 to 11 (9 to 7) 6 to 10 (13 to 6)
EF 4 to 7 (6) 4 to 9 (6 to 5) 4 to 7 (6) 3 to 8 (7 to 6)
CF nM (7 to 5) 4 to 6 (4) nM (4 to 3) 5 to 7 (3)
QL 5 to 9 (10 to 9) 7 to 13 (10 to 7) 5 to 9 (9) 7 to 12 (11 to 7)
PA 4 to 5 (10 to 7) 7 to 9 (16 to 9) 4 (11 to 7) 4 to 9 (15 to 8)
FA 4 to 14 (13 to 5) 9 to 15 (14 to 6) 6 to 13 (11 to 6) 9 to 15 (14 to 6)
NV 7 to 8 (8 to 5) 7 to 10 (7 to 6) 6 to 7 (8 to 6) 8 to 10 (7 to 6)
AP 17 to 18 (15 to 9) 12 to 14 (14 to 8) 16 (11 to 16) 12 to 14 (14 to 8)
DY nM (8 to 5) 8 (9 to 7) nM (6 to 4) 9 (8 to 5)
DI 5 (nM) nM (nM) 5 (nM) nM (nM)
SL nM (nM) nM (9) nM (nM) nM (9)
MIDs from the mean change method and the linear regression are useful for interpreting within-group and between-groups change, respectively.
The symptom scores were reversed to follow the functioning scales interpretation, i.e. 0 represents the worst possible score and 100, the best possible
score; no MID (nM) is used where no MID estimate is available either due to the absence of a suitable anchor or ES was either <0.2 or 0.8
Abbreviations: T1, T2 and T3 are time points for the start of treatment, end of treatment and end of follow-up, respectively. AP, appetite loss; CF,
cognitive functioning; CO, constipation; DI, diarrhoea; DY, dyspnoea; EF, emotional functioning; FA, fatigue; NV, nausea/vomiting; PA, pain;
PF, physical functioning, QL, global quality of life; RF, role functioning; SF, social functioning; SL, sleep disturbance; MID, minimally important
difference.
Fig. 1. Mean change and 95% confidence interval for improvement and deterioration EORTC QLQ-C30 scales, across multiple anchors
and at different time periods. Estimates are available only for scales with at least 1 suitable anchor or with effect size  0.2 and < 0.8
within the deteriorate and improve groups, respectively. These mean change scores are useful for interpreting within-group change over
time. Abbreviations: AP, appetite loss; CF, cognitive functioning; CO, constipation; DI, diarrhoea; DY, dyspnoea; EF, emotional
functioning; FA, fatigue; NV, nausea/vomiting; PA, pain; PF, physical functioning, QL, global quality of life; RF, role functioning; SF,
social functioning; SL, sleep disturbance. Deterioration Z worsened by 1 anchor category, no change Z no change in anchor category
and improvement Z improved by 1 category.
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Table 6
Summary of anchor-based MIDs for within- and between-group changes compared with distribution-based MID estimates.
Scale Anchor-based MID for within-
group change
Anchor-based MID for between-
groups change
Distribution-based QOL
scores at T1
(n Z 1829e1839)
T2eT1 T3eT2 T2eT1 T3eT2
Improvement
(deterioration)
Improvement
(deterioration)
Improvement
(deterioration)
Improvement
(deterioration)
0.2 SD 0.3 SD 0.5 SD 1 SEM
PF 6 (6) 5 (8) 5 (6) 6 (7) 3.7 5.6 9.4 5.6
RF 13 (6) 12 (10) 11 (9) 11 (11) 5.5 8.2 13.6 11.6
SF 8 (7) 9 (9) 7 (8) 8 (9) 4.5 6.8 11.3 8.2
EF 6 (6) 8 (5) 6 (6) 6 (6) 4.1 6.1 10.2 7.6
CF nM (6) 5 (4) nM (3) 6 (3) 3.6 5.4 8.9 7.6
QL 7 (9) 11 (9) 7 (9) 10 (10) 4.0 6.0 10.0 8.5
PA 4 (8) 8 (12) 4 (9) 7 (12) 4.4 6.6 11.0 8.2
FA 10 (8) 13 (11) 10 (8) 13 (11) 5.2 7.8 13.0 10.7
NV 7 (7) 9 (7) 7 (8) 9 (6) 2.9 4.3 7.2 8.7
AP 18 (12) 13 (11) 16 (13) 13 (11) 5.6 8.4 14.0 12.8
DY nM (7) 8 (8) nM (5) 9 (7) 4.3 6.4 10.7 8.8
DI 5 (nM) nM (nM) 5 (nM) nM (nM) 3.9 5.9 9.8 10.3
SL nM (4) nM (9) nM (4) nM (9) 5.2 7.8 12.9 11.3
CO nM (nM) nM (nM) nM (nM) nM (nM) 3.4 5.0 8.4 6.9
The within-group MIDs (from the mean change method) and the between-group MIDs (from the linear regression) were summarised via weighted
averages based on scale/anchor pair correlation.
The symptom scores were reversed to follow the functioning scales interpretation, i.e. 0 represents the worst possible score and 100, the best possible
score; no MID (nM) is used where no MID estimate is available either due to the absence of a suitable anchor or ES was either <0.2 or 0.8
Abbreviations: T1, T2 and T3 are time points for the start of treatment, end of treatment and end of follow-up, respectively. AP, appetite loss; CF,
cognitive functioning; CO, constipation; DI, diarrhoea; DY, dyspnoea; EF, emotional functioning; FA, fatigue; NV, nausea/vomiting; PA, pain;
PF, physical functioning, QL, global quality of life; RF, role functioning; SF, social functioning; SL, sleep disturbance; MID, minimally important
difference; SD, standard deviation; SEM, standard error of measurement.
Note: no suitable anchors were found for constipation.
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underestimation of their relevance by the physician-
rated anchors (such as performance status or CTCAE
grades) compared to the patient self-reported assess-
ment. However, given that our data set is limited, it will
be interesting to further examine this observation in
future studies. Anchors related to mental health/distress
of patients were not available in our study, which is a
notable lack because these are important aspects of
HRQOL. In addition, anchors that are based on the
patient’s perspective of change (e.g. subjective signifi-
cance questionnaires) were not available. Nonetheless, it
is reassuring to notice the considerable overlap between
our findings and those of Osoba et al. [4], which was
based on using individual patients’ ratings of change as
anchor. One out of the three trials that were pooled in
this study used version 2 of the EORTC QLQ-C30.
Although the scales were transformed to have values
between 0 and 100, the PF scale of version 2 can only
take a limited range of values compared to version 3. It
will be interesting to further investigate in a larger
sample if these differences may affect MID estimates.
Another limitation is that our data originate from three
controlled clinical trials, each with specific selection and
treatment criteria. Although results are consistent
among the three trials, extrapolation beyond their spe-
cific setting remains unverified.
In conclusion, our findings can help clinicians and re-
searchers to interpret the clinical relevance of group-levelchange of QLQ-C30 scores over time in patients with
malignant melanoma. We have provided MID estimates
for interpreting changes in HRQOL scores over time for
bothwithin the group and between the groups of patients.
Our results will also aid to performmore accurate sample
size calculations when primary outcomes are based on
EORTC QLQ-C30 scales.Funding
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Frequency of patients by change scores of anchors.
Anchor
change
score
CTCAE
nausea
CTCAE
anorexia
CTCAE
nervous
system
CTCAE
immune
CTCAE
gastrointestinal
CTCAE
diarrhoea
CTCAE
pain
CTCAE
fatigue
Performance
status
T2eT1 4 2 (0.1)
3 5 (0.3) 6 (0.3) 5 (0.3) 6 (0.7) 9 (0.5) 9 (0.5) 8 (0.4)
2 50 (2.7) 47 (2.6) 42 (2.3) 44 (4.9) 68 (3.7) 4 (0.4) 69 (3.8) 72 (3.9) 5 (0.3)
1 206 (11.2) 229 (12.5) 179 (9.8) 178 (19.8) 363 (19.8) 43 (4.6) 332 (18.2) 325 (17.7) 91 (5.6)
0 1491 (81.3) 1459
(79.6)
1404
(76.6)
563 (62.6) 1199 (65.4) 825 (88.3) 1166
(63.8)
1178
(64.3)
1373 (85)
1 71 (3.9) 77 (4.2) 151 (8.2) 85 (9.5) 158 (8.6) 53 (5.7) 199 (10.9) 201 (11.0) 136 (8.4)
2 10 (0.6) 13 (0.7) 38 (2.1) 19 (2.1) 30 (1.6) 8 (0.9) 48 (2.6) 41 (2.2) 9 (0.6)
3 2 (0.1) 13 (0.7) 4 (0.4) 6 (0.3) 1 (0.1) 6 (0.3) 6 (0.3) 1 (0.1)
4 1 (0.1)
Total 1833 1833 1833 899 1833 934 1829 1833 1615
T3eT2 4 1 (0.1) 3 (0.2) 4 (0.3) 1 (0.1) 2 (0.1)
3 3 (0.2) 4 (0.3) 13 (0.8) 10 (1.1) 19 (1.2) 6 (0.9) 9 (0.6) 12 (0.8) 2 (0.2)
2 15 (0.9) 19 (1.2) 19 (1.2) 10 (1.1) 46 (2.9) 10 (1.4) 32 (2) 43 (2.7) 11 (0.9)
1 63 (4) 61 (3.8) 145 (9.1) 68 (7.7) 145 (9.1) 45 (6.4) 182 (11.5) 185 (11.7) 120 (9.8)
0 1463 (92.2) 1440
(90.8)
1298
(81.8)
738 (83.7) 1283 (80.9) 638 (90.6) 1223
(77.1)
1208
(72.6)
982 (80.1)
1 31 (2) 44 (2.8) 78 (4.9) 40 (4.5) 63 (4) 2 (0.3) 108 (6.8) 99 (6.2) 93 (7.6)
2 7 (0.4) 14 (0.9) 22 (1.4) 13 (1.5) 21 (1.3) 3 (0.4) 27 (1.7) 32 (2) 15 (1.2)
3 3 (0.2) 4 (0.3) 8 (0.5) 1 (0.1) 4 (0.3) 4 (0.3) 4 (0.3) 3 (0.2)
4 2 (0.2) 1 (0.1) 1 (0.1)
Total 1586 1586 1586 882 1586 704 1586 1586 1226
CTCAE, common terminology criteria for adverse events; MID, minimally important difference.
T1, T2 and T3 are time points for the start of treatment, end of treatment and end of follow-up, respectively.
Anchor change scores: 4 to 1, 0 and 1 to 4 represent improvement, no change and deterioration, respectively. Only the 1, 0 and 1 change score
categories were used to estimate MIDs. No MIDs for deterioration were calculated for CTCAE diarrhoea between T2 and T3 because only 2
patients experienced a clinically minimal deterioration.
Table A.2
Means (effect sizes) of HRQOL change scores in three clinical change groups that are based on selected anchors per EORTC QLQ-C30 scale.
Scale Anchor T2eT1 T3eT2
Improvement
(ES)
n Z 43e363
No change
n Z 563e1491
Deterioration
(ES)
n Z 53e201
Improvement
(ES)
n Z 45e185
No change
n Z 638e1463
Deterioration
(ES)
n Z 31e108
PF Performance status 2.30 (0.16)a 0.24 6.42 (0.45) 4.93 (0.30) 1.03 8.86 (0.53)
CTCAE anorexia 7.13 (0.39) 0.80 1.30 (0.07)a 6.12 (0.34) 0.52 7.69 (0.43)
CTCAE fatigue 5.03 (0.28) 1.46 1.92 (0.11)a 3.91 (0.22) 0.73 6.05 (0.34)
RF CTCAE gastrointestinal 12.94 (0.48) 2.85 6.01 (0.22) 7.18 (0.28) 0.50 1.32 (0.05)a
CTCAE anorexia 15.36 (0.57) 2.94 2.38 (0.09)a 15.03 (0.58) 1.27 7.95 (0.31)
CTCAE fatigue 11.38 (0.43) 2.84 0.66 (0.02)a 10.90 (0.42) 1.11 8.84 (0.34)
Performance status 14.29 (0.56) 2.74 2.57 (0.10)a 15.69 (0.59) 1.31 14.31 (0.54)
SF CTCAE gastrointestinal 8.36 (0.38) 0.88 7.75 (0.35) 3.79 (0.17)a 0.00 6.28 (0.29)
CTCAE anorexia 11.26 (0.51) 0.68 8.33 (0.37) 10.00 (0.45) 0.56 11.24 (0.51)
CTCAE fatigue 5.68 (0.26) 1.67 4.92 (0.22) 5.89 (0.27) 0.29 6.77 (0.31)
Performance status 7.78 (0.37) 1.15 6.42 (0.30) 10.54 (0.47) 0.69 11.96 (0.53)
EF Performance status 2.44 (0.13)a 0.07 3.07 (0.16)a 7.75 (0.36) 0.82 5.25 (0.24)
CTCAE anorexia 4.20 (0.21) 0.07 5.81 (0.29) 8.75 (0.41) 0.91 5.56 (0.26)
CTCAE nervous system 7.08 (0.35) 0.19 2.31 (0.11)a 4.14 (0.20) 0.95 3.17 (0.15)a
CF Performance status 2.22 (0.15)a 2.79 7.04 (0.46) 3.92 (0.21) 1.13 2.90 (0.15)y
CTCAE nervous system 1.13 (0.06)a 1.91 4.92 (0.28) 5.06 (0.26) 0.66 4.06 (0.21)
CTCAE fatigue 0.77 (0.04)a 2.33 4.98 (0.28) 5.80 (0.30) 0.99 1.20 (0.06)a
QL CTCAE gastrointestinal 7.12 (0.36) 0.19 9.08 (0.46) 6.94 (0.33) 0.04 6.85 (0.33)
CTCAE anorexia 8.70 (0.44) 0.10 8.55 (0.43) 13.19 (0.63) 0.82 10.42 (0.50)
CTCAE nausea 6.40 (0.33) 0.51 8.57 (0.44) 10.05 (0.48) 0.69 9.17 (0.44)
Performance status 4.72 (0.25) 0.31 9.64 (0.52) 13.11 (0.61) 0.69 9.87 (0.46)
PA Performance status 4.95 (0.24) 0.68 7.35 (0.35) 7.64 (0.33) 0.27 15.59 (0.68)
Table A.2 (continued )
Scale Anchor T2eT1 T3eT2
Improvement
(ES)
n Z 43e363
No change
n Z 563e1491
Deterioration
(ES)
n Z 53e201
Improvement
(ES)
n Z 45e185
No change
n Z 638e1463
Deterioration
(ES)
n Z 31e108
CTCAE pain 3.92 (0.20) 0.06 6.62 (0.31) 8.79 (0.38) 0.48 8.49 (0.37)
CTCAE immune 4.40 (0.20) 0.51 10.39 (0.28) 6.62 (0.29) 2.28 2.92 (0.13)a
FA CTCAE gastrointestinal 11.20 (0.44) 0.54 7.17 (0.28) 9.43 (0.39) 0.70 5.64 (0.24)
CTCAE anorexia 13.71 (0.53) 0.53 4.47 (0.17)a 15.03 (0.62) 1.45 12.88 (0.53)
CTCAE fatigue 9.91 (0.39) 0.95 5.33 (0.21) 14.29 (0.59) 0.41 11.11 (0.46)
Performance status 4.27 (0.20) 1.95 12.54 (0.59) 14.44 (0.61) 0.35 14.40 (0.61)
NV CTCAE gastrointestinal 7.10 (0.53) 0.78 7.75 (0.57) 7.24 (0.59) 0.48 7.41 (0.60)
CTCAE anorexia 7.63 (0.55) 0.71 5.19 (0.38) 12.02 (0.90)a 0.15 6.44 (0.48)
CTCAE nausea 12.50 (0.92)a 0.47 13.62 (1.00)a 9.79 (0.77) 0.18 5.91 (0.46)
AP CTCAE gastrointestinal 16.94 (0.64) 1.04 10.34 (0.39) 13.85 (0.64) 0.13 8.20 (0.38)
CTCAE anorexia 23.16 (0.88)a 1.10 14.91 (0.56) 28.25 (1.29)a 0.49 14.29 (0.65)
CTCAE nausea 18.37 (0.68) 2.36 8.45 (0.31) 12.37 (0.56) 0.90 3.23 (0.15)a
DY Performance status 0.37 (0.02)a 2.08 8.33 (0.46) 3.33 (0.17)a 1.02 9.06 (0.47)
CTCAE fatigue 2.37 (0.11)a 1.26 5.03 (0.23) 8.15 (0.40) 1.14 6.46 (0.32)
DI CTCAE gastrointestinal 5.09 (0.27) 0.28 14.86 (0.80)a 16.20 (0.85)a 0.63 0.00 (0.00)a
CTCAE diarrhoea 20.16 (1.16)a 1.10 27.67 (1.59)a 31.85 (1.30)a 3.16 e
SL Performance status 2.20 (0.09)a 0.27 4.41 (0.17)a 3.89 (0.15)a 0.31 9.32 (0.35)
All the ESs for the no change group were <0.2.
The symptom scores were reversed to follow the functioning scales interpretation, i.e. 0 represents the worst possible score and 100, the best possible
score.
Abbreviations: T1, T2 and T3 are time points for the start of treatment, end of treatment and end of follow-up, respectively. AP, appetite loss; CF,
cognitive functioning; CO, constipation; DI, diarrhoea; DY, dyspnoea; EF, emotional functioning; FA, fatigue; NV, nausea/vomiting; PA, pain;
PF, physical functioning, QL, global quality of life; RF, role functioning; SF, social functioning; SL, sleep disturbance; CTCAE, common ter-
minology criteria for adverse events; ES, effect size; MID, minimally important difference; EORTC QLQ-C30, European Organisation for
Research and Treatment for Cancer Quality of life Questionnaire core 30.
No results are presented for deterioration in DI scale based on CTCAE diarrhoea between T2 and T3 because only 2 patients experienced a
clinically minimal deterioration.
a These estimated change scores were not considered to summarise the MID estimate because their ESs were either <0.2 or 0.8.
Table A.3
Mean change scores based on the linear regression.
Scale Anchor T2eT1 T3eT2
Improvement Deterioration Improvement Deterioration
PF Performance status 2.54a 6.18 5.96 7.84
CTCAE anorexia 6.32 2.10a 6.64 7.17
CTCAE fatigue 3.57 3.38a 4.64 5.32
RF CTCAE gastrointestinal 10.09 8.86 6.68 1.82a
CTCAE anorexia 12.42 5.32a 13.76 9.22
CTCAE fatigue 8.55 3.50a 9.79 9.95
Performance status 11.55 5.31a 14.38 15.63
SF CTCAE gastrointestinal 7.47 8.63 3.79a 6.28
CTCAE anorexia 10.58 9.01 9.44 11.80
CTCAE fatigue 4.01 6.58 5.59 7.06
Performance status 6.63 7.57 9.86 12.64
EF Performance status 2.37a 3.13a 6.93 6.07
CTCAE anorexia 4.27 5.74 7.84 6.47
CTCAE nervous system 6.90 2.50a 3.19 4.12a
CF Performance status 0.57a 4.24 5.05 1.77a
CTCAE nervous system 0.78a 3.01 5.72 3.40
CTCAE fatigue 1.55a 2.65 6.78 0.21a
QL CTCAE gastrointestinal 6.93 9.27 6.90 6.89
CTCAE anorexia 8.60 8.65 12.37 11.24
CTCAE nausea 5.90 9.08 9.37 9.85
Performance status 5.03 9.33 12.42 10.56
PA Performance status 4.26 8.03 7.91 15.32
CTCAE pain 3.97 6.56 9.27 8.01
CTCAE immune 3.90 10.90 4.34 5.20a
FA CTCAE gastrointestinal 10.66 7.72 8.73 6.34
(continued on next page)
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Table A.3 (continued )
Scale Anchor T2eT1 T3eT2
Improvement Deterioration Improvement Deterioration
CTCAE anorexia 13.18 5.00a 13.57 14.33
CTCAE fatigue 8.96 6.29 13.88 11.52
Performance status 6.22 10.59 14.79 14.05
NV CTCAE gastrointestinal 6.32 8.53 7.72 6.92
CTCAE anorexia 6.92 5.90 12.17a 6.29
CTCAE nausea 12.03a 14.09 9.97 5.73
AP CTCAE gastrointestinal 15.91 11.37 13.98 8.07
CTCAE anorexia 22.05a 16.02 27.76 14.77
CTCAE nausea 16.01 10.82 11.47 4.12a
DY Performance status 1.72a 6.25 4.36a 8.03
CTCAE fatigue 3.63a 3.77 9.29 5.33
DI CTCAE gastrointestinal 5.37 14.58a 15.57 0.63a
CTCAE diarrhoea 21.26a 26.57a 28.69 e
SL Performance status 2.47a 4.14a 4.20a 9.01
Separate regression models were fitted for each scale/anchor pair: OutcomeZHRQOL change score, covariateZ binary anchor variable, coded as
‘stable’ Z 0 and ‘improvement’ Z 1 or ‘deterioration’ Z 1 for models on improvement and deterioration, respectively. The mean change
scoresZ slope parameters. No results are presented for deterioration in DI scale based on CTCAE diarrhoea between T2 and T3 because only 2
patients experienced a clinically minimal deterioration.
Abbreviations: T1, T2 and T3 are time points for the start of treatment, end of treatment and end of follow-up, respectively. AP, appetite loss; CF,
cognitive functioning; CO, constipation; DI, diarrhoea; DY, dyspnoea; EF, emotional functioning; FA, fatigue; NV, nausea/vomiting; PA, pain;
PF, physical functioning, QL, global quality of life; RF, role functioning; SF, social functioning; SL, sleep disturbance; CTCAE, common ter-
minology criteria for adverse events; MID, minimally important difference; ES, effect size.
a These estimated change scores were not considered to summarise the MID estimate because their ES was either <0.2 or 0.8.
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